## **Section 1.0 – Study Overview NA**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Regulations are identified appropriately in application form: | Yes | No |  |
| 1. Multi-site research but not eligible for [CTO](http://www.ctontario.ca/)/[OCREB](https://ocreb.ca/about-ocreb/guidelines-templates-and-sops/) review: | Yes | No | N/A |
| 1. Start and end dates are realistic: | Yes | No |  |
| 1. No issues have been noted in previous REB reviews: | Yes | No |  |

Click here to enter text.

## **Section 2.0 – Study Details NA**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1. Supervisor added to ‘Project Info Tab’ for students & letter of support attached: | Yes | | No | | N/A |
| 1. Ethics training certificates/exemption attached to application or TRAQ user profile: | Yes | | No | |  |
| 1. Independent scientific review attached (only mandatory for higher risk studies): | Yes | | No | | N/A |
| 1. Additional approvals have been identified (e.g., TRAQ DSS, In-person research): | Yes | | No | | N/A |
| 1. For Indigenous and/or community based research a description of how the relevant community will be engaged or justification as to why the research is exempt from community engagement has been provided ([TCPS 2 Chapter 9](https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter9-chapitre9.html)). Documented support provided as required: | Yes | | No | | N/A |
| 1. The purpose/rationale for the research is acceptable and written in plain language: | | Yes | | No |  |
| 1. The study design/methodology is explained including information about compensation/reimbursement if appropriate: | | Yes | | No |  |
| 1. Implementation strategy and platforms specified for all methods and supporting documents attached: | | Yes | | No | N/A |
| 1. Secondary uses of data are explained: | | Yes | | No | N/A |

Click here to enter text.

## **Section 3.0 – Biological Specimen Collection NA**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. The collection, use, retention, labeling, transfer, security, future use of biological samples is described: | Yes | No | N/A |
| 1. The plan for the return of genetic testing results is described: | Yes | No | N/A |
| 1. Plan for disclosing/not disclosing incidental findings is described: | Yes | No | N/A |
| 1. Withdrawal of sample procedures are explained: | Yes | No | N/A |

Click here to enter text.

## **Section 4.0 – Imaging & Other Health Related Interventions NA**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Imaging sources identified and use is explained: | Yes | No | N/A |
| 1. Methodologies identified and implementation is explained: | Yes | No | N/A |

Click here to enter text.

## **Section 5.0 – Informed Consent NA**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Consent form reviewed against [HSREB LOI/ICF Checklist](https://www.queensu.ca/urs/ethics/queens-university-health-sciences-and-affiliated-teaching-hospitals-research-ethics-board) or CTO Checklist: | Yes | No | N/A |
| 1. Justification has been provided for any waivers or alterations to the consent process as per TCPS [Article 3.7A](https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter3-chapitre3.html#b): | Yes | No | N/A |
| 1. Justification has been provided for not obtaining consent for use of identifiable secondary biologicals/information as per TCPS [Article 12.3A](https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter12-chapitre12.html#c)/[Article 5.5A](https://ethics.gc.ca/eng/tcps2-eptc2_2018_chapter5-chapitre5.html#d): | Yes | No | N/A |
| 1. Informed consent process has been explained including strategies for minimizing coercion/power imbalance/undue influence and all applicable documents attached: | Yes | No | N/A |
| 1. Assent process explained for those not providing/unable to provide consent: | Yes | No | N/A |
| 1. Process for documenting the consent/assent process has been explained: | Yes | No | N/A |

Click here to enter text.

## **Section 6.0 – Risks and Benefits NA**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. All risks to participants/researchers have been identified and safety protocols have been explained: | Yes | No | N/A |
| 1. Plans to mitigate risks to participants/researchers and third parties 2. are explained: | Yes | No | N/A |
| 1. Benefits to society are explained and benefits to participants (or none) are explained: | Yes | No |  |

Click here to enter text.

## **Section 7.0 – Confidentiality NA**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Justification acceptable for collecting all Personal Information (PI) and / or sensitive information and / or Personal Health Information (PHI) and / or Demographic information: | Yes | No | N/A |
| 1. Types of information be collected identified appropriately (e.g., anonymous, anonymized/de-identified, secondary): | Yes | No |  |
| 1. Data collection forms provided and accurately reflect the collection of information: | Yes | No | N/A |
| 1. Personal Health Information will be encrypted if stored on a portable device: | Yes | No | N/A |
| 1. The type of information that could be generated from linking data sets is described AND adequate measures to protect confidentiality if identifiable information can be generated through the data linkage have been explained: | Yes | No | N/A |
| 1. Security measures if transmitting data to another site/Sponsor have been explained (secure file transfer, encryption): | Yes | No | N/A |
| 1. Measures for safeguarding information, for collection, use, dissemination, retention, long term plans (disposal/repository/store indefinitely) are explained: | Yes | No | N/A |

Click here to enter text.

## **Overall**

|  |  |  |  |
| --- | --- | --- | --- |
| 1. The plan for communication of the study results are explained: | Yes | No | N/A |
| 1. Funding disclosed/Budget is provided (mandatory for clinical trials only): | Yes | No | N/A |
| 1. Potential COIs are declared and adequately addressed: | Yes | No | N/A |
| 1. PI(s) qualified, CV attached (mandatory for clinical trials only) and PI attested: | Yes | No | N/A |
| 1. All questions have been completed: | Yes | No | N/A |

Click here to enter text.